BACKGROUND Transcatheter aortic and pulmonary valves have been used to treat stenosis or regurgitation after prior
T ranscatheter valve replacement has altered the therapeutic landscape for individuals with native and post-operative stenosis or regurgitation of the aortic, pulmonary, mitral, and tricuspid valves (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . In recent reports of data from the international VIVID registry (Valve-in-Valve
International Database Registry), it was shown that transcatheter tricuspid valve (TV) implantation after prior surgical repair or bioprosthetic valve replacement can be performed successfully and safely, with good short-term outcomes in most patients (6) (7) (8) . Although those early findings were encouraging, there is relatively little information about intermediate outcomes or associations between patient-related factors and valve-related outcomes after transcatheter TV replacement (TTVR). In patients who have undergone transcatheter aortic valve replacement, long-term durability, valve thrombosis, and to a lesser degree, endocarditis have emerged as important concerns (12) (13) (14) (15) , whereas recurrent obstruction and endocarditis are the most prominent adverse outcomes that have been observed after transcatheter pulmonary valve replacement (16, 17) . These observations are not surprising, insofar as all patients with a prosthetic valve are at risk for endocarditis (18) (19) (20) . Given these findings, it is important to understand valverelated outcomes after TTVR, including the epidemiology of post-intervention endocarditis and the impact of prior endocarditis. Therefore, we undertook the present study to evaluate mid-term outcomes in a large international cohort of patients who underwent TTVR after surgical TV repair or replacement.
METHODS PATIENTS AND PROCEDURES. Data were collected through the voluntary unsponsored
Valve-in-Valve International Database Registry, for patients with acquired or congenital heart disease (CHD) who underwent TTVR after prior TV repair (valve-in-ring) or replacement (valve-in-valve) surgery, as described previously (6) (7) (8) . TTVR procedures were performed clinically at the discretion of the implanting physician. Post-procedural antiplatelet or antithrombotic therapy was also determined by the treating clinicians. Data collected included basic demographic, historical, and diagnostic variables, procedural details, and followup information, as reported in prior studies (6) (7) (8) .
Follow-up data were actively collected through January 2018, when the database was locked for analysis. Patients with <3 years follow-up who were alive, reintervention-free, and had no follow-up visit entered in our database within the past 2 years were defined as lost to follow-up for this study. Patients who underwent transcatheter valve implantation in the tricuspid position of a modified Bjork Fontan (i.e., right atrium-to-right ventricle connection) were reported separately (21) and were not included in this study. For this follow-up outcomes study, we excluded patients who underwent catheterization with intention, but no attempt, to implant a valve (n ¼ 5) or an unsuccessful attempt to deliver a valve to the implant site (n ¼ 1), which were included in a prior report (6) . Institutional review boards at participating centers approved submission of data.
OUTCOMES AND DATA ANALYSIS. The primary outcomes evaluated for this study were TV function, Additional interventions were performed at the same catheterization in 47 patients (15%) (Online Table 1 ).
SHORT-TERM OUTCOMES. In 7 patients, the implan- Among the 244 patients who were alive and had not undergone reintervention, 184 had been followed for <3 years, 56 of whom were considered lost to follow-up according to the definition used for this study. Thirty-nine patients who were alive and reintervention-free had been followed for <1 year. T V r e i n t e r v e n t i o n . Thirty-one patients (10%) underwent reintervention on the TV during follow-up:
surgical TVR in 18 patients, a second TTVR within the first for malposition or dysfunction in 8 patients, redilation of the original TTVR in 3 patients, and device closure of paravalvar leak in 2 patients. Two other patients had the TTVR removed due to heart transplantation. Indications for reintervention are summarized in Table 2 . Four reinterventions were within the first month after TTVR and 10 were during the first 6 months. Five patients died after reintervention, 3 within 30 days and 2 at 6 to 7 months later.
The cumulative incidence of reintervention was 5% at (20) anomaly), and 1 had a prior history of endocarditis associated with intravenous drug use. Causative organisms are listed in Table 3 . By competing risk analysis, the estimated cumulative incidence of McElhinney et al.
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